A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas

Kenzo Sonoda, Manabu Nakashima, Tsunehisa Kaku, Toshiharu Kamura, Hitoo Nakano, Takeshi Watanabe

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

BACKGROUND. A large number of monoclonal antibodies (MoAbs) against human tumor cells have been generated and it has been shown that these MoAbs are useful tools in the diagnosis and treatment of cancer patients, as well as in the basic investigation of the oncogenesis and characterization of cancer cells. METHODS. The 22-1-1 MoAb was established by cell fusion between mouse myeloma cells and spleen cells derived from mice immunized with the human uterine cervical adenocarcinoma cell line, SiSo. The tissue distribution and biologic characteristics of the 22-1-1 antigen (Ag) were examined. RESULTS. The 22-1-1 Ag was distinct from the known tumor-associated antigens such as YH 206, GA 733, CA 125, carcinoembryonic antigen, and sialyl Le(x) molecules in an expression pattern in human tumor cell lines. An immunohistochemical study revealed that 22-1-1 Ag was expressed in 87.5% of uterine cervical adenocarcinomas, 66% of uterine endometrial adenocarcinomas, and 58.8% of ovarian carcinomas. Moreover, 22-1-1 Ag was detected in 87.7% of uterine cervical squamous cell carcinomas; however, it was not detected in normal uterine cervical or ovarian tissues, except in uterine endometrial glands, in which its expression was observed at low levels. The 22-1-1 Ag was secreted into cell culture supernatant fluids and was also detected in the vaginal discharges of uterine cervical carcinoma patients. The antigenic epitope of 22-1-1 Ag was shown to be a protein with a molecular weight of 78 kilodaltons using sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. CONCLUSIONS. The 22-1-1 MoAb reactive to a novel tumor-associated antigen was generated. This Ag was expressed in cancer cells derived mainly from the uterus and ovary. Moreover, 22-1-1 Ag was secreted in the vaginal discharges of uterine cervical carcinoma patients. 22-1-1 MoAb is a potential tool for the study of oncogenesis and the management of cancer patients.

Original languageEnglish
Pages (from-to)1501-1509
Number of pages9
JournalCancer
Volume77
Issue number8
DOIs
Publication statusPublished - Apr 15 1996

Fingerprint

Neoplasm Antigens
Carcinoma
Vaginal Discharge
Adenocarcinoma
Neoplasms
Carcinogenesis
CA-125 Antigen
Monoclonal Antibodies
Cell Fusion
Carcinoembryonic Antigen
Tissue Distribution
22-1-1 antigen
Tumor Cell Line
Sodium Dodecyl Sulfate
Uterus
Epitopes
Polyacrylamide Gel Electrophoresis
Squamous Cell Carcinoma
Ovary
Spleen

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. / Sonoda, Kenzo; Nakashima, Manabu; Kaku, Tsunehisa; Kamura, Toshiharu; Nakano, Hitoo; Watanabe, Takeshi.

In: Cancer, Vol. 77, No. 8, 15.04.1996, p. 1501-1509.

Research output: Contribution to journalArticle

Sonoda, Kenzo ; Nakashima, Manabu ; Kaku, Tsunehisa ; Kamura, Toshiharu ; Nakano, Hitoo ; Watanabe, Takeshi. / A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. In: Cancer. 1996 ; Vol. 77, No. 8. pp. 1501-1509.
@article{4620348c173740a3a1240b87e95b7376,
title = "A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas",
abstract = "BACKGROUND. A large number of monoclonal antibodies (MoAbs) against human tumor cells have been generated and it has been shown that these MoAbs are useful tools in the diagnosis and treatment of cancer patients, as well as in the basic investigation of the oncogenesis and characterization of cancer cells. METHODS. The 22-1-1 MoAb was established by cell fusion between mouse myeloma cells and spleen cells derived from mice immunized with the human uterine cervical adenocarcinoma cell line, SiSo. The tissue distribution and biologic characteristics of the 22-1-1 antigen (Ag) were examined. RESULTS. The 22-1-1 Ag was distinct from the known tumor-associated antigens such as YH 206, GA 733, CA 125, carcinoembryonic antigen, and sialyl Le(x) molecules in an expression pattern in human tumor cell lines. An immunohistochemical study revealed that 22-1-1 Ag was expressed in 87.5{\%} of uterine cervical adenocarcinomas, 66{\%} of uterine endometrial adenocarcinomas, and 58.8{\%} of ovarian carcinomas. Moreover, 22-1-1 Ag was detected in 87.7{\%} of uterine cervical squamous cell carcinomas; however, it was not detected in normal uterine cervical or ovarian tissues, except in uterine endometrial glands, in which its expression was observed at low levels. The 22-1-1 Ag was secreted into cell culture supernatant fluids and was also detected in the vaginal discharges of uterine cervical carcinoma patients. The antigenic epitope of 22-1-1 Ag was shown to be a protein with a molecular weight of 78 kilodaltons using sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. CONCLUSIONS. The 22-1-1 MoAb reactive to a novel tumor-associated antigen was generated. This Ag was expressed in cancer cells derived mainly from the uterus and ovary. Moreover, 22-1-1 Ag was secreted in the vaginal discharges of uterine cervical carcinoma patients. 22-1-1 MoAb is a potential tool for the study of oncogenesis and the management of cancer patients.",
author = "Kenzo Sonoda and Manabu Nakashima and Tsunehisa Kaku and Toshiharu Kamura and Hitoo Nakano and Takeshi Watanabe",
year = "1996",
month = "4",
day = "15",
doi = "10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3",
language = "English",
volume = "77",
pages = "1501--1509",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas

AU - Sonoda, Kenzo

AU - Nakashima, Manabu

AU - Kaku, Tsunehisa

AU - Kamura, Toshiharu

AU - Nakano, Hitoo

AU - Watanabe, Takeshi

PY - 1996/4/15

Y1 - 1996/4/15

N2 - BACKGROUND. A large number of monoclonal antibodies (MoAbs) against human tumor cells have been generated and it has been shown that these MoAbs are useful tools in the diagnosis and treatment of cancer patients, as well as in the basic investigation of the oncogenesis and characterization of cancer cells. METHODS. The 22-1-1 MoAb was established by cell fusion between mouse myeloma cells and spleen cells derived from mice immunized with the human uterine cervical adenocarcinoma cell line, SiSo. The tissue distribution and biologic characteristics of the 22-1-1 antigen (Ag) were examined. RESULTS. The 22-1-1 Ag was distinct from the known tumor-associated antigens such as YH 206, GA 733, CA 125, carcinoembryonic antigen, and sialyl Le(x) molecules in an expression pattern in human tumor cell lines. An immunohistochemical study revealed that 22-1-1 Ag was expressed in 87.5% of uterine cervical adenocarcinomas, 66% of uterine endometrial adenocarcinomas, and 58.8% of ovarian carcinomas. Moreover, 22-1-1 Ag was detected in 87.7% of uterine cervical squamous cell carcinomas; however, it was not detected in normal uterine cervical or ovarian tissues, except in uterine endometrial glands, in which its expression was observed at low levels. The 22-1-1 Ag was secreted into cell culture supernatant fluids and was also detected in the vaginal discharges of uterine cervical carcinoma patients. The antigenic epitope of 22-1-1 Ag was shown to be a protein with a molecular weight of 78 kilodaltons using sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. CONCLUSIONS. The 22-1-1 MoAb reactive to a novel tumor-associated antigen was generated. This Ag was expressed in cancer cells derived mainly from the uterus and ovary. Moreover, 22-1-1 Ag was secreted in the vaginal discharges of uterine cervical carcinoma patients. 22-1-1 MoAb is a potential tool for the study of oncogenesis and the management of cancer patients.

AB - BACKGROUND. A large number of monoclonal antibodies (MoAbs) against human tumor cells have been generated and it has been shown that these MoAbs are useful tools in the diagnosis and treatment of cancer patients, as well as in the basic investigation of the oncogenesis and characterization of cancer cells. METHODS. The 22-1-1 MoAb was established by cell fusion between mouse myeloma cells and spleen cells derived from mice immunized with the human uterine cervical adenocarcinoma cell line, SiSo. The tissue distribution and biologic characteristics of the 22-1-1 antigen (Ag) were examined. RESULTS. The 22-1-1 Ag was distinct from the known tumor-associated antigens such as YH 206, GA 733, CA 125, carcinoembryonic antigen, and sialyl Le(x) molecules in an expression pattern in human tumor cell lines. An immunohistochemical study revealed that 22-1-1 Ag was expressed in 87.5% of uterine cervical adenocarcinomas, 66% of uterine endometrial adenocarcinomas, and 58.8% of ovarian carcinomas. Moreover, 22-1-1 Ag was detected in 87.7% of uterine cervical squamous cell carcinomas; however, it was not detected in normal uterine cervical or ovarian tissues, except in uterine endometrial glands, in which its expression was observed at low levels. The 22-1-1 Ag was secreted into cell culture supernatant fluids and was also detected in the vaginal discharges of uterine cervical carcinoma patients. The antigenic epitope of 22-1-1 Ag was shown to be a protein with a molecular weight of 78 kilodaltons using sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. CONCLUSIONS. The 22-1-1 MoAb reactive to a novel tumor-associated antigen was generated. This Ag was expressed in cancer cells derived mainly from the uterus and ovary. Moreover, 22-1-1 Ag was secreted in the vaginal discharges of uterine cervical carcinoma patients. 22-1-1 MoAb is a potential tool for the study of oncogenesis and the management of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0029966641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029966641&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3

DO - 10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3

M3 - Article

C2 - 8608535

AN - SCOPUS:0029966641

VL - 77

SP - 1501

EP - 1509

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -